CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Trevena Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Trevena Inc
955 Chesterbrook Blvd Ste 110
Phone: (610) 354-8840p:610 354-8840 CHESTERBROOK, PA  19087-5627  United States Ticker: TRVNTRVN

Business Summary
Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/202012/31/2019YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board Leon O.Moulder 62 6/1/2013 6/1/2013
President, Chief Executive Officer, Director Carrie L.Bourdow 57 10/1/2018 5/4/2015
Chief Financial Officer, Senior Vice President BarryShin 48 6/25/2019 6/25/2019
8 additional Officers and Directors records available in full report.

Business Names
Business Name
Trevena, Inc.
TRVN

General Information
Number of Employees: 24 (As of 12/31/2019)
Outstanding Shares: 148,949,403 (As of 8/12/2020)
Shareholders: 7
Stock Exchange: NASD
Federal Tax Id: 261469215
Fax Number: (302) 636-5454
Email Address: admin@trevenainc.com


Copyright © 2020 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, September 29, 2020